DCM
UTHR icon

DG Capital Management’s United Therapeutics UTHR Stock Holding History

DG Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,000
Closed -$1.32M – 35
2023
Q2 		$1.32M Buy
+6,000
New +$1.33M 0.59% 25

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

DG Capital Management's UTHR Position: Q1 2026 in Review

DG Capital Management held its United Therapeutics (UTHR) position steady in Q1 2026 at 558 shares worth $331K. The position accounts for 0.1% of the portfolio, ranked #25.

DG Capital Management first reported a position in UTHR in Q4 2020 and has held it in 12 quarters since. The position peaked at $29.7M in Q4 2021. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • DG Capital Management held 558 shares of United Therapeutics worth $331K as of Q1 2026.
  • DG Capital Management left its United Therapeutics share count unchanged in Q1 2026.
  • United Therapeutics made up 0.1% of DG Capital Management's portfolio in Q1 2026, its #25 holding.
  • DG Capital Management first reported a position in United Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • DG Capital Management's United Therapeutics position peaked at $29.7M in Q4 2021.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on DG Capital Management's 13F filing for Q1 2026, filed 13 May 2026.